News and Events
Dietary glutamine may be linked to B-cell lymphomas in abdominal lymph nodes
Study provides evidence for different anatomic locations being linked to different biology in lymphoma.
Read MoreClinical trial researching immunotherapy for bladder cancer
A trial led by Andrea B. Apolo, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is studying combination drug therapy and immunotherapy for bladder and urinary tract cancer.
Read MoreAligned Blog: Knowledge is Power: The Value and Importance of Genetic Counseling
This year's U.S. Food and Drug Administration's 4th Annual National Black Family Cancer Awareness Week falls from June 13-19, 2024. In honor of the theme, "Engaging Generations," we invited Michaela Taylor, M.S., CGC, Cancer Genetics Counselor in the Genetics Branch to write about the value of genetic counseling for Black and African American people and how broaching this sometimes difficult topic can lead to empowerment.
Read MoreNIH scientists develop AI tool to predict how cancer patients will respond to immunotherapy
In a proof-of-concept study, CCR researchers developed an artificial intelligence (AI) tool that uses routine clinical data to predict whether someone’s cancer will respond to immune checkpoint inhibitors. The machine-learning model may help doctors determine if these immunotherapy drugs are effective for treating a patient’s cancer. The study, published June 3, 2024, in Nature Cancer, was led by Eytan Ruppin, M.D., Ph.D., Chief of the Cancer Data Science Laboratory, and collaborators at Memorial Sloan Kettering Cancer Center in New York.
Read MoreClinical trial researching combination immunotherapy for colorectal cancer
A trial led by Jason M. Redman, M.D., Assistant Research Physician in the Center for Immuno-Oncology, is studying combination immunotherapy for colorectal cancer.
Read MoreCelebrating CCR Careers: David D. Roberts, Ph.D.
David D. Roberts, Ph.D., a biochemist who identified a new pathway that controls cell responses to stress and developed approaches to improve cancer therapy by shutting it down, announces his retirement from the NCI.
Read MoreClinical trial researching drug therapy for neuroendocrine neoplasms
A trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is studying a new drug for neuroendocrine neoplasms, a group of rare cancers.
Read MoreMaster regulators flip the switch on neuroblastoma’s developmental state
Waves of regulatory changes can transform self-renewing neuroblastoma cells into neurons.
Read MoreBenign nail condition linked to rare syndrome that greatly increases cancer risk
Researchers from CCR and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) discovered the presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors. The study suggests conducting nail evaluation of affected patients and at-risk family members.
Read MoreAligned Blog: Building Community: Celebrating AANHPI Heritage Month
The COVID-19 pandemic highlighted an alarming trend in anti-Asian hate across the United States. To celebrate Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Heritage Month, Sonia A. Garcia, Ph.D., Scientific Diversity Program Manager in CCR's Office of Equity & Inclusion (OEI), highlights an NIH initiative created out of such adversity and shares the OEI's upcoming seminar series on advancing AANHPI folks into leadership positions.
Read MoreNew AI tool classifies brain tumors using images of tumor slides
A new artificial intelligence model has been found to be highly effective at identifying brain tumor subtypes — with 95% accuracy — simply by analyzing a standard pathology image of the tumor tissue.
Read More